1. Morgan E, Arnold M, Camargo MC, Gini A, Kunzmann AT, Matsuda T, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: A population-based modelling study. EClinicalMedicine. 2022; 47. doi.10.1016/j.eclinm.2022.101404 PMid:35497064 PMCid:PMC9046108

2. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229-63. doi.10.3322/caac.21834 PMid:38572751

3. Mocan L. Surgical Management of Gastric Cancer: A Systematic Review. J Clin Med. 2021; 10(12): 2557. doi.10.3390/jcm10122557 PMid:34207898 PMCid:PMC8227314

4. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513(7517): 202-9. doi.10.1038/nature13480 PMid:25079317 PMCid:PMC4170219

5. Bardakçi M, Ergun Y. Immunotherapy in gastric cancer with liver metastasis: Challenges and opportunities. World J Gastrointest Surg. 2024; 16(6): 1513-6. doi.10.4240/wjgs.v16.i6.1513 PMid:38983315 PMCid:PMC11230037

6. Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023; 16(1):57. doi.10.1186/s13045-023-01451-3 PMid:37245017 PMCid:PMC10225110

7. Qian CN, Mei Y, Zhang J. Cancer metastasis: issues and challenges. Chin J Cancer. 2017; 36(1): 38. doi.10.1186/s40880-017-0206-7 PMid:28372569 PMCid:PMC5379757

8. Lee WC, Kopetz S, Wistuba II, Zhang J. Metastasis of cancer: when and how? Ann Oncol. 2017; 28(9): 2045-7. doi.10.1093/annonc/mdx327 PMid:28911075

9. López MJ, Carbajal J, Alfaro AL, Saravia LG, Zanabria D, Araujo JM, et al. Characteristics of gastric cancer around the world. Crit Rev Oncol Hematol. 2023; 181: 103841. doi.10.1016/j.critrevonc.2022.103841 PMid:36240980

10. Bast RCJ, Croe CM, Hait WN, Hong WK, Kufe DW, Piccart-Gebhart M, et al. Holland-Frei Cancer Medicine. Somerset: John Wiley & Sons, Incorporated; 2017. doi.10.1002/9781119000822

11. Meirson T, Gil-Henn H, Samson AO. Invasion and metastasis: the elusive hallmark of cancer. Oncogene. 2020; 39(9): 2024-6. doi.10.1038/s41388-019-1110-1 PMid:31745295

12. Singh M, Yelle N, Venugopal C, Singh SK. EMT: Mechanisms and therapeutic implications. Pharmacol Ther. 2018;182:80-94. doi.10.1016/j.pharmthera.2017.08.009PMid:28834698

13. Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022; 15(1): 129. doi.10.1186/s13045-022-01347-8 PMid:36076302 PMCid:PMC9461252

14. Gao T, Li J zhi, Lu Y, Zhang C ying, Li Q, Mao J, et al. The mechanism between epithelial mesenchymal transition in breast cancer and hypoxia microenvironment. Biomed Pharmacother. 2016; 80: 393-405. doi.10.1016/j.biopha.2016.02.044 PMid:27133080

15. Shi R, Liao C, Zhang Q. Hypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications. Cells. 2021; 10(3):678. doi.10.3390/cells10030678 PMid:33808542 PMCid:PMC8003323

16. Zhang Y, Yapryntseva MA, Vdovin A, Maximchik P, Zhivotovsky B, Gogvadze V. Modeling hypoxia facilitates cancer cell survival through downregulation of p53 expression. Chem Biol Interact. 2021;345:109553. doi.10.1016/j.cbi.2021.109553 PMid:34126102

17. Nowak E, Bednarek I. Aspects of the Epigenetic Regulation of EMT Related to Cancer Metastasis. Cells. 2021;10(12):3435. doi.10.3390/cells10123435 PMid:34943943 PMCid:PMC8700111

18. Wigerup C, Påhlman S, Bexell D. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol Ther. 2016;164:152-69. doi.10.1016/j.pharmthera.2016.04.009 PMid:27139518

19. Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database Hallmark Gene Set Collection. Cell Syst. 2015;1(6):417-25. doi.10.1016/j.cels.2015.12.004 PMid:26771021 PMCid:PMC4707969

20. Frontiers CHG: A Systematically Integrated Database of Cancer Hallmark Genes [Internet]. [cited 2025 June 5].

21. COSMIC: the Catalogue of Somatic Mutations in Cancer Nucleic Acids Research Oxford Academic [Internet]. [cited 2025 June 5].

22. Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr Protoc Bioinforma. 2016; 54(1). doi.10.1002/cpbi.5 PMid:27322403

23. Yuan H, Yan M, Zhang G, Liu W, Deng C, Liao G, et al. CancerSEA: a cancer single-cell state atlas. Nucleic Acids Res. 2019; 47(D1): D900-8. doi.10.1093/nar/gky939 PMid:30329142 PMCid:PMC6324047

24. 24. Tong F, Xu L, Xu S, Zhang M. Identification of an autophagy-related 12-lncRNA signature and evaluation of NFYC-AS1 as a pro-cancer factor in lung adenocarcinoma. Front Genet. 2022;13. doi.10.3389/fgene.2022.834935 PMid:36105077 PMCid:PMC9466988

25. DiLeo MV, Strahan GD, Bakker M den, Hoekenga OA. Weighted Correlation Network Analysis (WGCNA) Applied to the Tomato Fruit Metabolome. PLOS ONE. 2011;6(10):e26683. doi.10.1371/journal.pone.0026683 PMid:22039529 PMCid:PMC3198806

26. Hou W, Kong L, Hou Z, Ji H. CD44 is a prognostic biomarker and correlated with immune infiltrates in gastric cancer. BMC Med Genomics. 2022;15(1):225. doi.10.1186/s12920-022-01383-w PMid:36316684 PMCid:PMC9620622

27. Liang G, Li S, Du W, Ke Q, Cai J, Yang J. Hypoxia regulates CD44 expression via hypoxia-inducible factor-1α in human gastric cancer cells. Oncol Lett. 2017;13(2):967-72. doi.10.3892/ol.2016.5473 PMid:28356986 PMCid:PMC5351347

28. HIF1A Overexpression Is Associated with Poor Prognosis in a Cohort of 731 Colorectal Cancers. Am J Pathol. 2010; 176(5): 2292-301. doi.10.2353/ajpath.2010.090972 PMid:20363910 PMCid:PMC2861094

29. Braicu EI, Luketina H, Richter R, Cacsire Castillo-Tong D, Lambrechts S, Mahner S, et al. HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer - a study of the OVCAD Consortium. OncoTargets Ther. 2014;7: 1563-9. doi.10.2147/OTT.S65373 PMid:25246800 PMCid:PMC4166345

30. Chen J, Fu Y, Hu J, He J. Hypoxia-related gene signature for predicting LUAD patients' prognosis and immune microenvironment. Cytokine. 2022; 152: 155820. doi.10.1016/j.cyto.2022.155820 PMid:35176657

31. Sun Y, Li Y, Wu J, Tian H, Liu H, Fang Y, et al. Nomograms for prediction of overall and cancer-specific survival in young breast cancer. Breast Cancer Res Treat. 2020;184(2):597-613. doi.10.1007/s10549-020-05870-5 PMid:32886273

32. Liang W, Zhang L, Jiang G, Wang Q, Liu L, Liu D, et al. Development and Validation of a Nomogram for Predicting Survival in Patients With Resected Non-Small-Cell Lung Cancer. J Clin Oncol. 2015;33(8): 861-9. doi.10.1200/JCO.2014.56.6661PMid:25624438

33. Tian H, Shi H, Yu J, Ge S, Ruan J. Biophysics Role and Biomimetic Culture Systems of ECM Stiffness in Cancer EMT. Glob Chall. 2022; 6(6): 2100094. doi.10.1002/gch2.202100094 PMid:35712024 PMCid:PMC9189138

34. Manuelli V, Pecorari C, Filomeni G, Zito E. Regulation of redox signaling in HIF-1-dependent tumor angiogenesis. FEBS J. 2022;289(18):5413-25. doi.10.1111/febs.16110 PMid:34228878

35. D'Ignazio L, Batie M, Rocha S. Hypoxia and Inflammation in Cancer, Focus on HIF and NF-κB. Biomedicines. 2017; 5(2): 21. doi.10.3390/biomedicines5020021 PMid:28536364 PMCid:PMC5489807

36. McGettrick AF, O'Neill LAJ. The Role of HIF in Immunity and Inflammation. Cell Metab. 2020; 32(4): 524-36. doi.10.1016/j.cmet.2020.08.002 PMid:32853548

37. Malkov MI, Lee CT, Taylor CT. Regulation of the Hypoxia-Inducible Factor (HIF) by Pro-Inflammatory Cytokines. Cells. 2021;10(9):2340. doi.10.3390/cells10092340 PMid:34571989 PMCid:PMC8466990

38. Tamura R, Tanaka T, Akasaki Y, Murayama Y, Yoshida K, Sasaki H. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications. Med Oncol. 2019; 37(1):2 .doi.10.1007/s12032-019-1329-2 PMid:31713115

39. Chen L, Lin G, Chen K, Liang R, Wan F, Zhang C, et al. VEGF promotes migration and invasion by regulating EMT and MMPs in nasopharyngeal carcinoma. J Cancer. 2020; 11(24): 7291-301. doi.10.7150/jca.46429 PMid:33193893 PMCid:PMC7646165

40. Hashimoto Y, Tsuzuki-Nakao T, Kida N, Matsuo Y, Maruyama T, Okada H, et al. Inflammatory Cytokine-Induced HIF-1 Activation Promotes Epithelial-Mesenchymal Transition in Endometrial Epithelial Cells. Biomedicines. 2023;11(1):210. doi.10.3390/biomedicines11010210 PMid:36672719 PMCid:PMC9855875